• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Chinese guidelines for diagnosis and treatment of follicular lymphoma(2023)].

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):529-534. doi: 10.3760/cma.j.issn.0253-2727.2023.07.001.

DOI:10.3760/cma.j.issn.0253-2727.2023.07.001
PMID:37749030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10509619/
Abstract
摘要

相似文献

1
[Chinese guidelines for diagnosis and treatment of follicular lymphoma(2023)].[中国滤泡性淋巴瘤诊断与治疗指南（2023年版）]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):529-534. doi: 10.3760/cma.j.issn.0253-2727.2023.07.001.
2
[Chinese guidelines for diagnosis and treatment of follicular lymphoma(2013)].[中国滤泡性淋巴瘤诊断与治疗指南（2013年）]
Zhonghua Xue Ye Xue Za Zhi. 2013 Sep;34(9):820-4. doi: 10.3760/cma.j.issn.0253-2727.2013.09.020.
3
[Chinese guidelines for the diagnosis and treatment of follicular lymphoma].[滤泡性淋巴瘤诊断与治疗中国专家共识]
Zhonghua Xue Ye Xue Za Zhi. 2011 Oct;32(10):717-20.
4
[Chinese guidelines for the diagnosis and treatment of follicular lymphoma].[滤泡性淋巴瘤诊断与治疗中国指南]
Zhonghua Xue Ye Xue Za Zhi. 2011 Nov;32(11):804-7.
5
[Chinese guidelines for diagnosis and treatment of follicular lymphoma (2020)].[中国滤泡性淋巴瘤诊断与治疗指南（2020年版）]
Zhonghua Xue Ye Xue Za Zhi. 2020 Jul 14;41(7):537-544. doi: 10.3760/cma.j.issn.0253-2727.2020.07.002.
6
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发滤泡性淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v83-v90. doi: 10.1093/annonc/mdw400.
7
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发的滤泡性淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2011 Sep;22 Suppl 6:vi59-63. doi: 10.1093/annonc/mdr388.
8
Guidelines on the investigation and management of follicular lymphoma.滤泡性淋巴瘤的调查与管理指南
Br J Haematol. 2012 Feb;156(4):446-67. doi: 10.1111/j.1365-2141.2011.08969.x. Epub 2011 Dec 23.
9
[Recent progress in diagnosis and treatment of pediatric follicular lymphoma].[儿童滤泡性淋巴瘤的诊断与治疗新进展]
Zhonghua Er Ke Za Zhi. 2012 Mar;50(3):203-5.
10
Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.新诊断及复发滤泡性淋巴瘤：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:119-20. doi: 10.1093/annonc/mdp148.

本文引用的文献

1
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.滤泡性淋巴瘤诊断时的 EZH2 突变：指导一线治疗的有前途的生物标志物。
BMC Cancer. 2022 Sep 14;22(1):982. doi: 10.1186/s12885-022-10070-z.
2
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.RELEVANCE 研究：来那度胺联合利妥昔单抗（R）对比利妥昔单抗-化疗后利妥昔单抗维持治疗未经治疗的晚期滤泡性淋巴瘤的 6 年结果。
J Clin Oncol. 2022 Oct 1;40(28):3239-3245. doi: 10.1200/JCO.22.00843. Epub 2022 Aug 10.
3
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
4
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.成熟淋巴细胞肿瘤国际共识分类：临床咨询委员会报告。
Blood. 2022 Sep 15;140(11):1229-1253. doi: 10.1182/blood.2022015851.
5
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.阿基仑赛注射液治疗复发或难治性惰性非霍奇金淋巴瘤（ZUMA-5）：一项单臂、多中心、2 期临床试验。
Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8.
6
Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China.1845 例滤泡性淋巴瘤患者的临床特征和结局：中国真实世界多中心经验。
J Hematol Oncol. 2021 Aug 23;14(1):131. doi: 10.1186/s13045-021-01139-6.
7
Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies.PI3Kδ抑制剂YY-20394用于B细胞血液系统恶性肿瘤患者的1期临床试验。
J Hematol Oncol. 2021 Aug 23;14(1):130. doi: 10.1186/s13045-021-01140-z.
8
Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.在中国，针对接受过大量预处理的复发/难治性大 B 细胞淋巴瘤的成人患者，使用 Relmacabtagene autoleucel（relma-cel）CD19 CAR-T 疗法。
Cancer Med. 2021 Feb;10(3):999-1011. doi: 10.1002/cam4.3686. Epub 2020 Dec 31.
9
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.塔西美替尼治疗复发或难治性滤泡性淋巴瘤患者的疗效：一项开放标签、单臂、多中心、2 期临床试验。
Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6.
10
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.AUGMENT：来那度胺联合利妥昔单抗与安慰剂联合利妥昔单抗治疗复发或难治性惰性淋巴瘤的 III 期研究。
J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21.